In total our best estimates for PEX1-ZSD based only on known variants suggests that there are approximately 500 patients, the majority exhibiting an intermediate phenotype, across the United States, United Kingdom, Germany, France, Italy, Spain, and Japan (Figure 4), with distinct genetic variant and geographic distributions. Here, PEX1 is linked to peroxisome biogenesis disorder.